Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.

Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, Pellegrini M, Sokal E, Vertruyen A.

Vaccine. 2010 Oct 21;28(45):7331-6. doi: 10.1016/j.vaccine.2010.08.075. Epub 2010 Sep 15.

PMID:
20813217
2.

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G.

Vaccine. 2009 Nov 16;27(49):6959-65. doi: 10.1016/j.vaccine.2009.08.101. Epub 2009 Sep 12.

PMID:
19751689
3.

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.

Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A.

Pediatr Infect Dis J. 2009 Jul;28(7):563-71. doi: 10.1097/INF.0b013e31819d6394.

PMID:
19561422
4.
5.

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.

Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.

Vaccine. 2012 Jul 13;30(33):5030-7. doi: 10.1016/j.vaccine.2012.03.053. Epub 2012 Apr 1.

PMID:
22472791
6.

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.

Banzhoff A, Haertel S, Praus M.

Hum Vaccin. 2011 May;7(5):539-48. Epub 2011 May 1.

PMID:
21422814
7.

Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.

Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G.

Vaccine. 2015 Jan 1;33(1):174-81. doi: 10.1016/j.vaccine.2014.10.085. Epub 2014 Nov 11.

PMID:
25444803
8.

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.

Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M.

Vaccine. 2009 Oct 23;27(45):6291-5. doi: 10.1016/j.vaccine.2009.02.004.

PMID:
19840662
9.

Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R.

Pediatrics. 2010 Oct;126(4):e762-70. doi: 10.1542/peds.2009-2628. Epub 2010 Sep 6.

PMID:
20819892
10.

Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers.

Hwang SM, Kim HL, Min KW, Kim M, Lim JS, Choi JM, Chun BC, Kim MJ, Lee SM, Kim SY, Jeon HH.

Jpn J Infect Dis. 2012;65(3):193-7.

11.

Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.

Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G.

Pediatr Infect Dis J. 2014 Dec;33(12):e320-9. doi: 10.1097/INF.0000000000000462.

PMID:
24978857
12.

Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.

Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, Mosca F, Principi N.

Pediatrics. 2011 May;127(5):e1161-8. doi: 10.1542/peds.2010-1920. Epub 2011 Apr 4.

PMID:
21464195
13.

A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.

Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli C, Groth N, Levin Y, Del Giudice G.

Hum Vaccin Immunother. 2014;10(6):1701-10. doi: 10.4161/hv.28618. Epub 2014 Apr 14.

14.

MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.

El Sahly H.

Expert Rev Vaccines. 2010 Oct;9(10):1135-41. doi: 10.1586/erv.10.111. Review.

PMID:
20923265
15.

Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.

Solares AR, Aragon CG, Pivaral RU, Prado-Cohrs D, Sales-Carmona V, Pellegrini M, Groth N.

J Infect Dev Ctries. 2014 Sep 12;8(9):1160-8. doi: 10.3855/jidc.4594.

16.

Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study.

Della Cioppa G, Vesikari T, Sokal E, Lindert K, Nicolay U.

Vaccine. 2011 Nov 3;29(47):8696-704. doi: 10.1016/j.vaccine.2011.08.111. Epub 2011 Sep 9.

PMID:
21906647
17.

Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.

Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N.

Pediatr Infect Dis J. 2012 Apr;31(4):e59-65. doi: 10.1097/INF.0b013e31824b9545.

PMID:
22418661
18.

Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.

Zuccotti GV, Pariani E, Scaramuzza A, Santoro L, Giani E, Macedoni M, Gazzarri A, Anselmi G, Amendola A, Zanetti A.

Diabet Med. 2011 Dec;28(12):1530-6. doi: 10.1111/j.1464-5491.2011.03449.x.

PMID:
21916971
19.

Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.

Dell'Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S.

Vaccine. 2012 Jan 20;30(5):936-40. doi: 10.1016/j.vaccine.2011.11.083. Epub 2011 Dec 3.

PMID:
22138210
20.

Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis.

Tsai T, Kyaw MH, Novicki D, Nacci P, Rai S, Clemens R.

Vaccine. 2010 Feb 17;28(7):1877-80. doi: 10.1016/j.vaccine.2009.11.077. Epub 2009 Dec 5.

PMID:
19969117

Supplemental Content

Support Center